Not sure how smart it'd be for Altria to spend an additional ~billion on a US CBD company for an already underachieving and oversaturated US CBD market. Cron was their investment into the cannabis space just like Canopy is Constellation's. They knew progress would be pending on US cannabis policy reform. Canopy's Acreage deal to enter the US is still pending and may never happen. Medmen was supposed to be the US brand for Cron/Altria to absorb into the umbrella but that didn't quite workout.
News 
Market Data 
Discover 
AI
